Travere Therapeutics Insider Trades
NASDAQ: TVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 0 · $0
- Sales
- 60 · $70.08M
- Shares bought / sold
- 0 / 1.13M
- Net activity
- Net selling $70.1 million
Travere Therapeutics insider activity
Over the last 12 months, Travere Therapeutics insiders reported 100 transactions on SEC Form 4: 0 open-market purchases and 60 sales. Insiders bought $0 and sold $70.1 million worth of stock, for net insider selling of $70.1 million. The largest seller was Dube Eric M, with $26.4 million in reported sales.
The most recent filing shows Heerma Peter (EVP, CHIEF COMMERCIAL OFFICER) reporting a transaction in 8,282 shares at $22.40 on Sep 17, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put TVTX's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
TVTX insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Sep 17, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 6,802 | $441.80K | Form 4 |
| Sep 17, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 101,691 | $6.57M | Form 4 |
| Sep 17, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Option exercise | 108,493 | $2.53M | Form 4 |
| Sep 17, 2026 | Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Sale | 8,282 | $538.92K | Form 4 |
| Sep 17, 2026 | Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Option exercise | 8,282 | $185.52K | Form 4 |
| Sep 16, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 96,125 | $6.12M | Form 4 |
| Sep 16, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 99,716 | $6.31M | Form 4 |
| Sep 16, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Option exercise | 195,841 | $4.57M | Form 4 |
| Sep 16, 2026 | Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Sale | 79,113 | $5.04M | Form 4 |
| Sep 16, 2026 | Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Sale | 93,604 | $5.92M | Form 4 |
| Sep 16, 2026 | Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Option exercise | 17,717 | $476.23K | Form 4 |
| Sep 16, 2026 | Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Option exercise | 55,000 | $850.30K | Form 4 |
| Sep 16, 2026 | Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Option exercise | 100,000 | $1.13M | Form 4 |
| Sep 16, 2026 | ROTE WILLIAM E.Chief Research Officer | Sale | 47,746 | $3.04M | Form 4 |
| Sep 16, 2026 | ROTE WILLIAM E.Chief Research Officer | Sale | 65,104 | $4.11M | Form 4 |
| Sep 16, 2026 | ROTE WILLIAM E.Chief Research Officer | Option exercise | 57,500 | $1.55M | Form 4 |
| Sep 16, 2026 | ROTE WILLIAM E.Chief Research Officer | Option exercise | 55,000 | $850.30K | Form 4 |
| Sep 16, 2026 | ROTE WILLIAM E.Chief Research Officer | Option exercise | 350 | $6.29K | Form 4 |
| Sep 15, 2026 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | Sale | 300 | $19.10K | Form 4 |
| Sep 15, 2026 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | Sale | 800 | $50.28K | Form 4 |
| Sep 15, 2026 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | Sale | 4,275 | $265.63K | Form 4 |
| Sep 15, 2026 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | Option exercise | 1,625 | $33.25K | Form 4 |
| Sep 15, 2026 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | Option exercise | 1,250 | $28.00K | Form 4 |
| Sep 15, 2026 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | Option exercise | 2,500 | $68.75K | Form 4 |
| Sep 15, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | Sale | 400 | $26.12K | Form 4 |
| Sep 15, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | Sale | 1,900 | $121.00K | Form 4 |
| Sep 15, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | Sale | 20,735 | $1.30M | Form 4 |
| Sep 15, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | Sale | 27,473 | $1.70M | Form 4 |
| Sep 15, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | Option exercise | 20,000 | $348.80K | Form 4 |
| Sep 15, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 270 | $17.63K | Form 4 |
| Sep 15, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 3,102 | $197.42K | Form 4 |
| Sep 15, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 28,796 | $1.80M | Form 4 |
| Sep 15, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 63,498 | $3.94M | Form 4 |
| Sep 15, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Option exercise | 95,666 | $2.23M | Form 4 |
| Sep 15, 2026 | REED ELIZABETH EChief Legal Officer and GC | Sale | 300 | $19.59K | Form 4 |
| Sep 15, 2026 | REED ELIZABETH EChief Legal Officer and GC | Sale | 1,400 | $89.17K | Form 4 |
| Sep 15, 2026 | REED ELIZABETH EChief Legal Officer and GC | Sale | 13,874 | $868.96K | Form 4 |
| Sep 15, 2026 | REED ELIZABETH EChief Legal Officer and GC | Sale | 21,926 | $1.36M | Form 4 |
| Sep 15, 2026 | REED ELIZABETH EChief Legal Officer and GC | Option exercise | 37,500 | $579.75K | Form 4 |
| Sep 15, 2026 | Inrig JulaEVP, Head of R&D & CMO | Sale | 400 | $26.12K | Form 4 |
| Sep 15, 2026 | Inrig JulaEVP, Head of R&D & CMO | Sale | 1,600 | $101.90K | Form 4 |
| Sep 15, 2026 | Inrig JulaEVP, Head of R&D & CMO | Sale | 17,284 | $1.08M | Form 4 |
| Sep 15, 2026 | Inrig JulaEVP, Head of R&D & CMO | Sale | 25,390 | $1.57M | Form 4 |
| Sep 15, 2026 | Inrig JulaEVP, Head of R&D & CMO | Option exercise | 32,395 | $289.29K | Form 4 |
| Sep 15, 2026 | Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Sale | 1,431 | $93.46K | Form 4 |
| Sep 15, 2026 | Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Sale | 1,400 | $89.11K | Form 4 |
| Sep 15, 2026 | Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Sale | 27,421 | $1.72M | Form 4 |
| Sep 15, 2026 | Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Sale | 71,938 | $4.46M | Form 4 |
| Sep 15, 2026 | Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Option exercise | 36,526 | $326.18K | Form 4 |
| Sep 15, 2026 | Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Option exercise | 1,381 | $30.93K | Form 4 |
| Sep 15, 2026 | Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Option exercise | 39,283 | $1.06M | Form 4 |
| Sep 15, 2026 | ROTE WILLIAM E.Chief Research Officer | Sale | 270 | $17.63K | Form 4 |
| Sep 15, 2026 | ROTE WILLIAM E.Chief Research Officer | Sale | 3,000 | $190.95K | Form 4 |
| Sep 15, 2026 | ROTE WILLIAM E.Chief Research Officer | Sale | 29,021 | $1.82M | Form 4 |
| Sep 15, 2026 | ROTE WILLIAM E.Chief Research Officer | Sale | 63,907 | $3.96M | Form 4 |
| Sep 15, 2026 | ROTE WILLIAM E.Chief Research Officer | Option exercise | 39,650 | $712.11K | Form 4 |
| Sep 15, 2026 | ROTE WILLIAM E.Chief Research Officer | Option exercise | 39,000 | $984.75K | Form 4 |
| Sep 10, 2026 | Meckler Jeffrey ADirector | Sale | 3,100 | $211.07K | Form 4 |
| Sep 10, 2026 | Meckler Jeffrey ADirector | Sale | 14,000 | $944.49K | Form 4 |
| Sep 10, 2026 | Meckler Jeffrey ADirector | Sale | 1,200 | $79.38K | Form 4 |
| Sep 10, 2026 | Meckler Jeffrey ADirector | Sale | 1,700 | $111.17K | Form 4 |
| Sep 10, 2026 | Meckler Jeffrey ADirector | Option exercise | 10,000 | $265.20K | Form 4 |
| Sep 10, 2026 | Meckler Jeffrey ADirector | Option exercise | 10,000 | $174.40K | Form 4 |
| Sep 2, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | Sale | 642 | $42.61K | Form 4 |
| Aug 18, 2026 | LYONS GARY ADirector | Sale | 900 | $57.47K | Form 4 |
| Aug 18, 2026 | LYONS GARY ADirector | Sale | 4,100 | $259.39K | Form 4 |
| Aug 18, 2026 | LYONS GARY ADirector | Option exercise | 5,000 | $87.20K | Form 4 |
| Aug 17, 2026 | LYONS GARY ADirector | Sale | 500 | $32.08K | Form 4 |
| Aug 17, 2026 | LYONS GARY ADirector | Sale | 2,600 | $165.10K | Form 4 |
| Aug 17, 2026 | LYONS GARY ADirector | Sale | 1,900 | $118.80K | Form 4 |
| Aug 17, 2026 | LYONS GARY ADirector | Option exercise | 5,000 | $87.20K | Form 4 |
| Jun 22, 2026 | Inrig JulaCHIEF MEDICAL OFFICER | Gift | 468 | — | Form 4 |
| Jun 12, 2026 | Baynes Roy D.Director | Sale | 4,500 | $225.00K | Form 4 |
| Jun 12, 2026 | Baynes Roy D.Director | Option exercise | 4,500 | $96.21K | Form 4 |
| Jun 12, 2026 | Coughlin TimothyDirector | Sale | 10,000 | $500.75K | Form 4 |
| Jun 12, 2026 | Coughlin TimothyDirector | Option exercise | 10,000 | $265.20K | Form 4 |
| May 19, 2026 | Baynes Roy D.Director | Award | 4,000 | — | Form 4 |
| May 19, 2026 | Bruhn Suzanne LouiseDirector | Award | 4,000 | — | Form 4 |
| May 19, 2026 | Coughlin TimothyDirector | Award | 4,000 | — | Form 4 |
| May 19, 2026 | LYONS GARY ADirector | Award | 4,000 | — | Form 4 |
| May 19, 2026 | Orwin John ADirector | Award | 4,000 | — | Form 4 |
| May 19, 2026 | Poole SandraDirector | Award | 4,000 | — | Form 4 |
| May 19, 2026 | Squarer RonDirector | Award | 4,000 | — | Form 4 |
| May 19, 2026 | Meckler Jeffrey ADirector | Award | 4,000 | — | Form 4 |
| May 19, 2026 | Williams Brinkley RuthDirector | Award | 4,000 | — | Form 4 |
| May 15, 2026 | Coughlin TimothyDirector | Sale | 3,250 | $141.34K | Form 4 |
| May 6, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | Sale | 310 | $13.62K | Form 4 |
| May 6, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 22,500 | $988.88K | Form 4 |
| May 6, 2026 | REED ELIZABETH EChief Legal Officer and GC | Sale | 2,076 | $91.24K | Form 4 |
| May 6, 2026 | ROTE WILLIAM E.Chief Research Officer | Sale | 2,763 | $121.43K | Form 4 |
| May 6, 2026 | Inrig JulaCHIEF MEDICAL OFFICER | Sale | 311 | $13.67K | Form 4 |
| May 5, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | Sale | 2,181 | $101.74K | Form 4 |
| May 5, 2026 | Heerma PeterCHIEF COMMERCIAL OFFICER | Sale | 2,174 | $101.42K | Form 4 |
| May 5, 2026 | REED ELIZABETH EChief Legal Officer and GC | Sale | 2,174 | $101.42K | Form 4 |
| May 5, 2026 | Inrig JulaCHIEF MEDICAL OFFICER | Sale | 2,174 | $101.42K | Form 4 |
| May 5, 2026 | Baynes Roy D.Director | Sale | 4,500 | $209.93K | Form 4 |
| May 5, 2026 | Baynes Roy D.Director | Option exercise | 4,500 | $82.22K | Form 4 |
| May 4, 2026 | Inrig JulaCHIEF MEDICAL OFFICER | Option exercise | 20,000 | $448.00K | Form 4 |
| May 4, 2026 | Meckler Jeffrey ADirector | Sale | 8,000 | $360.00K | Form 4 |
| May 4, 2026 | Meckler Jeffrey ADirector | Option exercise | 8,000 | $130.64K | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4